Search

Metformin is the most widely used oral antidiabetic agent for the treatment of type 2 diabetes (T2D) and the association of the use of this drug with vitamin B12 deficiency has been described. A review of studies was carried out to find out the evidence of this association and the recommendations for its detection, prevention and treatment. The reported prevalence of vitamin B12 deficiency in patients treated with metformin ranged from 5.8% to 52% in the different series. Older patients, those who received metformin at high doses and for a longer time, and those who do not consume food of animal origin, are those who are at greater risk of suffering from this deficit.

This Consensus comes to light in the midst of one of the worst global health crises in the last 100 years. SARS-CoV-2 and its clinical manifestation, COVID-19, have caused a disruption in how doctors and patients interact. Although it is an infectious disease, one of the most notable characteristics is that its mortality increases in patients with chronic non-communicable diseases and, in particular, with a history of diabetes and cardiovascular disease. In this context, then, we believe that the recommendations made in this document, which aim to identify and protect these patients, become more relevant, while the implementation, beyond the statements, of specific cardiometabolic prevention policies becomes a priority.

Introduction: the recommendations of the Argentine Ministry of Health (MSAL) to provide immunization throughout the life is vaccination. Unlike the child and youth population, most of adults do not receive vaccination according to the current recommendations. Objectives: to describe the immunization schemes that people with diabetes mellitus should receive.

Introduction: dislipemia prevalence in type 2 diabetes is very often, between 35 to 56%; and despite new therapeutic options, statins continue being the drugs of first choice for treatment. Objectives: analyze the possible pharmacological interactions between statins and non-insulin drugs used in type 2 diabetic patients to normalize blood glucose. Inhibition of statins on HMG-CoA is highly selective, so pharmacodynamic interactions are not expected. But regarding pharmacokinetics, there are several levels where interactions with other drugs may occur. Three main levels of pharmacokinetic interactions have been described so far: membrane transporter OATP1B1, cytochrome P450 and absorption.

Type 2 diabetes mellitus requires multiple pharmacological treatment in order to achieve therapeutic goals and control comorbidities. Therefore, treatment leads to drug interaction. It means that the observed effects, whether therapeutic or adverse, are the result of the concomitant administration of two or more drugs given to a patient. This concept should be extended to foods, cosmetics and environmental substances. For many years, drug interactions were studied in a descriptive-empirical way, but in the last decades the participating mechanisms were hierarchized. Pharmacokinetic interactions involve absorptive, distributive and elimination processes in which enzymes and transport molecules are involved. Nowadays there is an even greater interest in the latter as a source of interactions. The purpose of this paper is to describe the transporters involved in the pharmacokinetics of oral antidiabetic agents , and in this way to realize if there could potentially be any interference when another drug is added.

Objectives: 1) update the Guidelines for the Treatment of the Diabetes Mellitus Type 2 of the Argentine Society of Diabetes, published in 2010; 2) provide to the health team updated guidance for the therapeutic management of people with this disease. Material and methods: a group of experts, full members of the Argentine Society of Diabetes, was convened to analyze the papers available from different sources, classifying them according to their level of evidence (Table 2), written in bold at the end of the paragraph; on this basis the 2010 guideline was modified to update contents. A drafting committee responsable for the final layout of the document was appointed. Conclusions: changes in lifestyle remain the first therapeutic option, metformin is the drug of first line, if there are no contraindications for use or intolerance, any of the other families of antidiabetic drugs, insulin and insulin analogs, can be used as monotherapy or associated, taking into account their contraindicationsand not using together those with similar action mechanisms. Algorithms 1 and 2 can be considered the synthesis of the current proposal.

Symposium 16: Diagnosis and management of diabetic dyslipidemia Pharmacological treatment (statins and drug combination) Statins constitute the undisputed pharmacological treatment of the diabetic dyslipidemia. Guidelines recommend using statins of moderate to high intensity as the first line of treatment, based on the fact that they reduce cardiovascular risk beyond the LDL cholesterol level. However, even when receiving maximum doses of this drug, not everyone reaches the target established of LDL cholesterol. Many patients need to add non-statin lipid-lowering agents for a combined treatment.